The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Rossi, Francesca ^a,b   Bernardo, Maria Ester ^b   Bellini, Giulia ^a   Luongo, Livio ^a,c   Conforti, Antonella ^b   Manzo, Iolanda ^a   Guida, Francesca ^a   Cristino, Luigia ^c,d   Imperatore, Roberta ^c,d   Petrosino, Stefania ^c,d   Nobili, Bruno ^a,b   Di Marzo, Vincenzo ^c,d   Locatelli, Franco ^b,e   Maione, Sabatino ^a,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c Endocannabinoid Research Group   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL FUNCTION; CELL HOMING; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; MEDIATOR; MESENCHYMAL STROMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

ADULT; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SURVIVAL; CYTOKINES; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOMODULATION; INFLAMMATION MEDIATORS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84896704785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080022     Document Type: Article

References (36)

1. Bernardo ME, Locatelli F, Fibbe WE (2009) Mesenchymal stromal cells. Ann N Y Acad Sci 1176: 101-117.
2. Bernardo ME, Cometa AM, Pagliara D, Vinti L, Rossi F, et al. (2011) Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol 24: 73-81.
3. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317. (Pubitemid 44269669)
4. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, et al. (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395. (Pubitemid 41671625)
5. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL (2000) Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9: 841-848. (Pubitemid 32110282)
6. Kim DH, Yoo KH, Choi KS, Choi J, Choi SY, et al. (2005) Gene expression profile of cytokine and growth factor during differentiation of bone marrowderived mesenchymal stem cell. Cytokine 31: 119-126. (Pubitemid 40910227)
7. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB (2010) Proinflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5: e9016.
8. Keating A (2012) Mesenchymal stromal cells: new directions. Cell Stem Cell 10: 709-716.
9. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, et al. (2012) Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 12: 574-591.
10. Figueroa FE, Carrión F, Villanueva S, Khoury M (2012) Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res 45: 269-277.
11. Pistoia V, Raffaghello L (2010) Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Rev Clin Immunol 6: 211-218.
12. Casiraghi F, Perico N, Remuzzi G (2013) Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 18: 51-58.
13. Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, et al. (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5: e8688.
14. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
15. Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, et al. (2010) 1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1, 4-dihydroindeno[1,2-c]pyr-azole- 3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis 37: 177-185.
16. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
17. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
18. 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133: 124-131.
19. Klein TW, Lane B, Newton CA, Friedman H (2000) The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225: 1-8.
20. Do Y, McKallip R, Nagarkatti M, Nagarkatti P (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-κB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173: 2373-2382. (Pubitemid 39063093)
21. Rossi F, Bellini G, Alisi A, Alterio A, Maione S, et al. (2012) Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. PLoS One 7: e42259.
22. Rossi F, Bellini G, Tolone C, Luongo L, Mancusi S, et al. (2012) The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res 66: 88-94.
23. Rossi F, Mancusi S, Bellini G, Roberti D, Punzo F, et al. (2011) CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura. Haematologica 96: 1883-1885.
24. Rossi F, Bellini G, Nobili B, Maione S, Perrone L, et al. (2011) Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: an alternative way to highlight the CB2 hepatoprotective properties. Hepatology 54: 1102.
25. Compagnucci C, Di Siena S, Bustamante MB, Di Giacomo D, Di Tommaso M, et al. (2013) Type-1 (CB(1)) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells. PLoS One. 8: e54271.
26. Jiang S, Alberich-Jorda M, Zagozdzon R, Parmar K, Fu Y, et al. (2011) Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood 117: 827-838.
27. Bari M, Tedesco M, Battista N, Pasquariello N, Pucci M, et al. (2011) Characterization of the endocannabinoid system in mouse embryonic stem cells. Stem Cells Dev 20: 139-147.
28. Jiang S, Fu Y, Williams J, Wood J, Pandarinathan L, et al. (2007) Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One; 2: e641.
29. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, et al. (2009) The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44: 476-484.
30. Rossi F, Bellini G, Luongo L, Torella M, Mancusi S, et al. (2011) The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone 48: 997-1007.
31. Stella N (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56: 244-253.
32. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, et al. (2009) The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106: 11131-11136.
33. Scutt A, Williamson EM (2007) Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 80: 50-59. (Pubitemid 46098877)
34. Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, et al. (2008) Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26: 279-289.
35. Correa F, Mestre L, Docagne F, Guaza C (2005) Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145: 441-448. (Pubitemid 40966273)
36. Contartese A, Valoti M, Corelli F, Pasquini S, Mugnaini C, et al. (2012) A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury. Pharmacol Res 66: 555-563.